Cardiology 2015-2019 Flashcards
(153 cards)
What is the clinical utility of circulating trimethylamine N-oxide in regards to dogs wiith MVD w/ or w/o CHF?
Dogs w/ CHF had higher concentrations compared to those w/o
JVIM 2019
A pilot study investigating circulating trimethylamine N‐oxide and its precursors in dogs with degenerative mitral valve disease with or without congestive heart failure
What are general prognositc indicators for increased likelihood of death with presumed MVD?
Dogs w/ higher NT-proBNP and cTNI higher HR older dogs femals exercise intolerance Receiving diuretics JVIM 2019 Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary‐care veterinary practices in the United Kingdom
What are some general factors associated w/ disease progression in preclinical MVD?
Increased plasma NT-proBNP HR, HR intensity presence of a cough CKCS breed pimobendan administration
Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom JVIM 2019
Is synthetic BNP1-32 a viable treatment option in dogs with MVD?
No positive impactive on urine output, BP or HR.
Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease JVIM 2019
What additional echocardiographic abnormalities (beyond chamber size) are present in dogs with preclinical DMVD
Regurgitant fraction ≥50%, EROA (effective regurgitant orifice area) body surface area ≥0.347 and QMR:QAo ≥0.79 were strongly associated with LA:Ao ≥1.6 and LVIDdN ≥1 are better than chamber size to determine severity of disease.
Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease (JVIM 2019)
What are the known clinical and lab findings that correlate with a short survival time in dogs with heart disease?
cachexia, clinically important tachyarrhythmias, azotemia, and being under‐ or overweight were associated with shorter survival times
Clinical and laboratory findings and survival time associated with cardiac cachexia in dogs with congestive heart failure (JVIM 2019)
What was the hazard ratio of LVIDDN and LA:Ao noted in the EPIC study?
Hazard ratio for a 0.1 increase:
LVIDDN: 1.26
LA:Ao 1.14
At day 35, heart size had reduced in the pimobendan group: median change in (Δ) LVIDDN −0.06 and LA:Ao −0.08
Cardiomegaly values:
LA:Ao > 1.6
LVDDN > 1.7
VHA 10.5
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
JVIM 2018
In one small study of echocardiographic what findings was most tightly associated with prognosis?
LAVmax (> 3.53 ml/KG appears the strongest predictor of cardiac death, being superior to LA/Ao and STE-derived variables.
Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease Jvim 2018
What is the noted survival time for dogs with advanced heart failure?
281 days median (8 months)
Clinical findings and survival time in dogs with advanced heart failure
JVIM 2018
What are some prognostic factors for dogs with advanced heart disease?
Dose of pimobendan, furosemide, spironolactone
Clinical findings and survival time in dogs with advanced heart failure
JVIM 2018
Can treatment of CHF based on NT-proBNP levels?
Possible - treatment success based only on NT-proBNP and no other values
Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease JVIM 2018
Are right or left sided atrioventricular accessory pathways more common?
Right
Atrioventricular accessory pathways in 89 dogs: Clinical features and outcome after radiofrequency catheter ablation (JVIM 2018)
What is the typical signalment of a dog with an atrioventricular accessory pathway?
GI signs with tachyardia
male labradors overrepresented
Atrioventricular accessory pathways in 89 dogs: Clinical features and outcome after radiofrequency catheter ablation (JVIM 2018)
What is the overall success rate of radiofrequency catheter ablation?
98.8% of dogs
Complication in 5/89
recurrence in 3 - responded to second procedure
Atrioventricular accessory pathways in 89 dogs: Clinical features and outcome after radiofrequency catheter ablation (JVIM 2018)
What are the noted affects of Entresto in dogs?
Reduces progression of urinary aldosterone to creatinine ratio
No affect on NT-prBNP
No diff in echo, thoracic radiographs, SAP or serum biochemical testing
Safe drug
A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (JVIM 2018)
Is thoracic ultrasound an adquate surrogate to thoracic radiographs for detection of pulmonary edema?
The use of B lines results in sens 90% and spec of 93%
Assessment of ultrasound B lines in dogs with different stages of chronic valvular heart disease (JVIM 2017)
What is the clinical relevance of mitral regurgitation severity as a predicting factor for young CKCS?
Hazard ratio of 3 for predictions of death with the presence of intermittent moderate or moderate to severe MR
Males with moderate to severe had a sig all cause mortality compared to females
Mitral regurgitation severity and left ventricular systolic dimension predict survival in young Cavalier King Charles Spaniels (JVIM 2017)
Is there any affect of body position, exercise or sedation for estimation of pulmonary artery pressure in dogs?
Sedation changed values in up 78% of dogs
Effect of body position, exercise, and sedation on estimation of pulmonary artery pressure in dogs with degenerative AV valve disease (JVIM 2017)
What correlations have been drawn between kidney and cardiac disease and how may they affect survival time?
MMVD had increase prevalence of CKD and anemia
Stage of cardiac disease nd stage of kidney disease were sig correlated
Severe heart disease, severe kidney disease, advanced age at the time of diagnosis and the use of furosemide associated with shorter survival time
(JVIM 2016)
What correlation exists between leptin and adiponectin in dogs with MMVD?
Leptin was higher in class 3 vs class 1-2 cardiac Adiponectin sig lower in class 1 vs healthy and sig higher in class 3 compared to class 1
Serum concentrations of leptin and adiponectin in dogs with MMVD (JVIM 2016)
Has there been success in implimenting breeding restrictions in CKCS?
MMVD has decreased in the breed over 8-10 years
Breeding restrictions decrease the prevalence of MMVD in CKCS over an 8- to 10-year period (JVIM 2016)
What is the clinical benfit for the administration of pimobendan in dogs with stage B2 disease?
Prolonged preclinical period by 15 months
Effect of Pimobendan in dogs w/ preclinical MMVD and cardiomegaly: the EPIC study – a randomized clinical trial
(JVIM 2016)
What is the cut-off for pulmonary vein to pulmonary artery ration to predict CHF in dogs?
1.7
Sens 96% and spect 91%
Pulmonary vein-to-pulmonary artery ratio is an echocardiographic index of CHF in dogs w/ MMVD (JVIM 2015)
How does the biopsy of left atrial tissue differ from left ventricular tissue in dogs with MVD?
Left ventricule is hypertrophied
LA is degenerate with immune cell infiltration and fibrosis
Pathologic manifestations on surgical biopsy and their correlation with clinical indices in dogs with MMVD (JVIM 2015)